LOAMU
LGND icon

Lombard Odier Asset Management (USA)’s Ligand Pharmaceuticals LGND Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-20,198
Closed -$1.71M – 278
2018
Q4 		$1.71M Buy
+20,198
New +$2.15M 0.13% 145

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s LGND Position: Q1 2019 in Review

Lombard Odier Asset Management (USA) sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 20,198 shares — an estimated $1.71M sold.

Lombard Odier Asset Management (USA) first reported a position in LGND in Q4 2018 and held it in 1 quarter. The position peaked at $1.71M in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Lombard Odier Asset Management (USA) reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 20,198 Ligand Pharmaceuticals shares in Q1 2019, an estimated $1.71M.
  • Lombard Odier Asset Management (USA) first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Lombard Odier Asset Management (USA)'s Ligand Pharmaceuticals position peaked at $1.71M in Q4 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2019, filed 15 May 2019.